Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon beta in multiple sclerosis].

J M Prieto1, M Lema

  • 1Unidad de Enfermedades Desmielinizantes, Servicio de Neurología, Hospital Clínico Universitario de Ciencias Neurológicas de Galicia P. Barrié de la Maza, Santiago de Compostela, España. meprieto@usc.es

Revista De Neurologia
|May 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].

Revista de neurologia·2024
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].

Revista de neurologia·2024
Same author

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.

Neurologia·2024
Same author

13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (II).

Revista de neurologia·2021
Same author

13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (I).

Revista de neurologia·2021
Same author

[The prevalence of multiple sclerosis in the city of Ourense, Galicia, in the north-west of the Iberian Peninsula].

Revista de neurologia·2020
Same journal

The Correlation Between and Variability of Three Balance Scales in the Assessment of Balance Function in Patients With Ataxia.

Revista de neurologia·2026
Same journal

Surgical Treatment of an Aneurysm in the Subacute Stage of Hemorrhagic Moyamoya Disease: Aneurysm Resection Combined With STA-MCA Bypass: A Case Report.

Revista de neurologia·2026
Same journal

Mapping the Evidence: Central Sleep Apnea Syndromes During Sleep and Stroke-A Scoping Review.

Revista de neurologia·2026
Same journal

Developmental and Epileptic Encephalopathy Due to a Novel <i>ARHGEF9</i> Deletion Variant: Case Series of Two Siblings.

Revista de neurologia·2026
Same journal

P300 Event-Related Potentials as Cognitive Biomarkers in Neurological and Neuropsychiatric Disorders: A Systematic Review.

Revista de neurologia·2026
Same journal

[Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache].

Revista de neurologia·2026
See all related articles

Three interferons effectively reduce multiple sclerosis relapses in relapsing-remitting forms. Early treatment with interferon beta-1a may slow disease progression, with generally good tolerability.

Area of Science:

  • Neurology
  • Immunology

Context:

  • Multiple sclerosis (MS) treatment landscape.
  • Limited understanding of interferon mechanisms in MS.
  • Discrepancies in optimal dosing and administration routes for interferons.

Purpose:

  • To review clinical trials of three available interferons for multiple sclerosis.
  • To analyze comparative studies between different interferon therapies.
  • To assess interferon effectiveness across various MS forms (relapsing-remitting, isolated neurologic syndromes, secondary progressive).

Summary:

  • Interferons demonstrate efficacy in reducing relapse frequency in relapsing-remitting MS.
  • Intramuscular interferon formulations show fewer skin-related side effects.
  • Evidence suggests interferon beta-1a (intramuscular) is effective in secondary progressive MS, while subcutaneous interferon beta-1b data shows regional discrepancies.

Related Experiment Videos

  • Early initiation of subcutaneous interferon beta-1a may delay disease progression.

    • Impact:

    • Provides a comprehensive overview of interferon efficacy in multiple sclerosis management.
    • Highlights the importance of early treatment initiation for disease modification.
    • Informs clinical decisions regarding interferon selection, dosing, and administration routes.
    • Identifies areas of ongoing research and clinical debate, such as optimal interferon therapy for specific MS subtypes.